 CENTOGENE N.V. CNTG, a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced changes to its Supervisory Board. Mr. Jacob Kaluski, a member of the Supervisory Board since 2014, has decided to resign from his office with effect from March 16, 2020. The Supervisory Board would like to thank Mr. Kaluski for his valuable contributions to CENTOGENEs success over the past six years, during which CENTOGENE has developed into a leading contributor in the battle against rare diseases. 